Itoh Kyogo, Takahashi Ryuji, Yoshitomi Munehiro, Terasaki Mizuhiko, Noguchi Masanori
Department of Immunology and Immunotherapy, Kurume University School of Medicine.
Nihon Rinsho. 2012 Dec;70(12):2118-23.
We conducted personalized peptide vaccination (PPV) for various types of advanced cancers in the past 10 years. A maximum of four HLA-matched peptides, which were selected based on the pre-existing host immunity before vaccination, were subcutaneously administered at PPV trials. Randomized phase II trial for patients with castration resistant prostate cancer showed the favorite clinical responses in the PPV group. PPV was also conducted for recurrent or progressive glioblastoma multiforme patients with median overall survival of 10.6 months, resulting in the initiation of randomized phase III clinical trial. A randomized phase III trial is essential to prove clinical benefits of PPV.
在过去10年里，我们对各类晚期癌症开展了个性化肽疫苗接种（PPV）。在PPV试验中，根据接种前宿主已有的免疫力选择最多四种HLA匹配的肽进行皮下注射。针对去势抵抗性前列腺癌患者的随机II期试验显示，PPV组有良好的临床反应。我们也对复发性或进展性多形性胶质母细胞瘤患者进行了PPV，这些患者的总中位生存期为10.6个月，这使得随机III期临床试验得以启动。随机III期试验对于证明PPV的临床益处至关重要。
